Antiplatelet Effects of Clopidogrel Vs Aspirin in Virologically Controlled HIV: A Randomized Controlled Trial.
JACC Basic Transl Sci
; 7(11): 1086-1097, 2022 Nov.
Article
em En
| MEDLINE
| ID: mdl-36687270
ABSTRACT
Patients with HIV exhibit platelet activation and increased risk of cardiovascular disease, the prevention of which is not fully known. Fifty-five HIV-positive patients were randomized to clopidogrel, aspirin, or no-treatment for 14 days, and the platelet phenotype and ability to induce endothelial inflammation assessed. Clopidogrel as opposed to aspirin and no-treatment reduced platelet activation (P-selectin and PAC-1 expression). Compared with baseline, platelet-induced proinflammatory transcript expression of cultured endothelial cells were reduced in those assigned to clopidogrel, with no change in the aspirin and no-treatment arms. In HIV, clinical trials of clopidogrel to prevent cardiovascular disease are warranted. (Antiplatelet Therapy in HIV; NCT02559414).
ADP, adenosine diphosphate; AIDS, acquired immunodeficiency virus; ART, antiretroviral therapy; CV, cardiovascular; CVD, cardiovascular disease; HIV; HIV, human immunodeficiency virus; HUVEC, human umbilical vein endothelial cell; MFI, mean fluorescence intensity; PWH, persons with HIV; aspirin; clopidogrel; endothelium; platelets
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article